Cargando…
Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861
Immunotoxins do not only bind to cancer-specific receptors to mediate the elimination of tumor cells through the innate immune system, but also increase target cytotoxicity by the intrinsic toxin activity. The plant glycoside SO1861 was previously reported to enhance the endolysosomal escape of anti...
Autores principales: | Panjideh, Hossein, Niesler, Nicole, Weng, Alexander, Fuchs, Hendrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318199/ https://www.ncbi.nlm.nih.gov/pubmed/35878216 http://dx.doi.org/10.3390/toxins14070478 |
Ejemplares similares
-
Correction: Panjideh et al. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861. Toxins 2022, 14, 478
por: Panjideh, Hossein, et al.
Publicado: (2022) -
Magnetic Nanoparticle-Based Dianthin Targeting for Controlled Drug Release Using the Endosomal Escape Enhancer SO1861
por: Zarinwall, Ajmal, et al.
Publicado: (2021) -
Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies
por: Fuchs, Hendrik, et al.
Publicado: (2017) -
Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861
por: Bhargava, Cheenu, et al.
Publicado: (2017) -
Dianthin and Its Potential in Targeted Tumor Therapies
por: Fuchs, Hendrik
Publicado: (2019)